Newsroom | 22767 results

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. Using its patented HYFT® Deep Data technology, MindWalk identified a functional pattern embedded in influenza biology that remains intact...

DURHAM, N.C.--(BUSINESS WIRE)--Naveris, Inc., the leader in precision oncology diagnostics for viral-driven cancers, today announced that it will be highlighting new data supporting the use of blood-based ctDNA tests to improve post-treatment surveillance protocols in both head-and-neck and anal cancers at the 44th Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA. Recent data published in Cancers reinforces the value of the Naveris Tumor Tissue Modi...

SCHLIEREN, Schweiz--(BUSINESS WIRE)--Die Virometix AG, ein Biotechnologieunternehmen mit Schwerpunkt auf der klinischen Entwicklung und Wegbereiter auf dem Gebiet der vollsynthetischen Impfstoffe, meldete heute positive Topline-Daten aus der Phase-1-Studie zu seinem führenden Produkt V-212 – einem serotypunabhängigen Pneumokokken-Impfstoffkandidaten, der zur Prävention von Pneumokokken-Erkrankungen infolge einer Infektion mit Streptococcus pneumoniae (Spn) entwickelt wird. Die Studie evaluierte...

SCHLIEREN, Svizzera--(BUSINESS WIRE)--Virometix AG, pionieristica azienda biotecnologica di fase clinica specializzata nello sviluppo di vaccini totalmente sintetici, oggi ha riferito dati interinali positivi dallo studio di fase 1 sul suo asset principale V-212, un candidato vaccino pneumococcico indipendente dal sierotipo, in fase di sviluppo, per la prevenzione delle infezioni da Streptococcus pneumoniae (Spn). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la...

SCHLIEREN, Zwitserland--(BUSINESS WIRE)--Virometix AG, een biotechnologiebedrijf in de klinische fase dat baanbrekend werk verricht op het gebied van volledig synthetische vaccins, heeft vandaag positieve resultaten bekendgemaakt van de Fase 1-studie met V-212, een serotype-onafhankelijk kandidaat-vaccin voor de preventie van pneumokokkenziekte veroorzaakt door Streptococcus pneumoniae (Spn)-infecties. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als...

SCHLIEREN, Suisse--(BUSINESS WIRE)--Virometix AG, une société de biotechnologie de stade clinique pionnière dans le domaine des vaccins entièrement synthétiques, a annoncé aujourd’hui les résultats positifs de l’essai de phase I mené sur son produit principal, V-212, un candidat vaccin antipneumococcique indépendant du sérotype, en cours de développement pour la prévention des maladies pneumococciques causées par des infections à Streptococcus pneumoniae (Spn). L’étude a évalué la sécurité et l...

SCHLIEREN, Suiza--(BUSINESS WIRE)--Virometix AG, una compañía biotecnológica en fase clínica pionera en el desarrollo de vacunas totalmente sintéticas, anunció hoy resultados preliminares positivos del ensayo de fase 1 de V-212, su principal candidato de vacuna neumocócica independiente del serotipo que se encuentra en desarrollo a los fines de prevenir la enfermedad neumocócica causada por infecciones de Streptococcus pneumoniae (Spn). El comunicado en el idioma original es la versión oficial...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time. About Arcturus Found...

MIAMI--(BUSINESS WIRE)--A new study from the University of Miami Public Health Policy Lab and the AHF Global Public Health Institute sheds light on why public trust broke down during the COVID-19 pandemic—and what can be done to rebuild it before the next health emergency. Drawing on interviews with government, academic, and private-sector leaders across Florida, the study found that distrust in public health grew due to a lack of transparency, political tensions, and inconsistent communication...

PARIS--(BUSINESS WIRE)--Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has raised €20.7 million (US$25 million) in a Seed financing. The round was co-led by Elaia, Pfizer Ventures and Bpifrance, as part of the InnoBio investment strategy, with participation from Wallonie Entreprendre, Argobio Studio, MACSF, The Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital. En...